New York, NY – For decades, the presence of regulatory T (Treg) cells in solid tumors has been a harbinger of grim prognoses, signaling a dampened immune response that allows cancer to flourish. These crucial immune cells typically act as the body’s internal "brakes," preventing autoimmune attacks but inadvertently hindering the immune system’s ability to combat malignant growths. Yet, colorectal cancer (CRC) has stubbornly defied this conventional wisdom, presenting a perplexing paradox where higher numbers of Treg cells often correlate with improved patient survival. This enduring mystery has long frustrated oncologists and immunologists alike, impeding the development of effective immunotherapies for the vast majority of CRC patients.
Now, a groundbreaking study from the esteemed Sloan Kettering Institute at Memorial Sloan Kettering Cancer Center (MSK) has finally cracked this enigmatic code. Published in the prestigious scientific journal Immunity, the research unveils a critical distinction: not all Treg cells are created equal. This pivotal discovery reveals that within colorectal tumors, two distinct subtypes of Treg cells exist, each playing diametrically opposing roles in disease progression. This nuanced understanding promises to revolutionize immunotherapy strategies, not only for colorectal cancer but potentially for a range of other cancers originating in tissues constantly exposed to environmental stresses, such as the skin and the lining of the stomach, mouth, and throat.
"Instead of the regulatory T cells promoting tumor growth, as they do in most cancers, in colorectal cancer we discovered there are actually two distinct subtypes of Treg cells that play opposing roles—one restrains tumor growth, while the other fuels it," states Alexander Rudensky, PhD, co-senior author of the study and chair of the Immunology Program at MSK, as well as a Howard Hughes Medical Institute Investigator. "It’s these beneficial Treg cells that make the difference, and this underscores the need for selective approaches."
The Enigma of Treg Cells in Cancer
Regulatory T cells, or Tregs, are a specialized subset of T lymphocytes that are indispensable for maintaining immune homeostasis and preventing autoimmunity. Their primary function is to suppress immune responses, ensuring that the body does not attack its own healthy tissues—a process known as immune tolerance. Without Tregs, the immune system would run rampant, leading to severe autoimmune diseases. However, this very mechanism becomes a double-edged sword in the context of cancer. In many solid tumors, Tregs infiltrate the tumor microenvironment, where they effectively neutralize the body’s anti-cancer immune cells, such as cytotoxic CD8+ T cells, allowing tumors to evade immune surveillance and grow unchecked. This suppression is a major hurdle for immunotherapeutic interventions, which aim to unleash the immune system against cancer.
Colorectal cancer, however, has consistently presented a counter-narrative. Clinical observations repeatedly showed that CRC patients with a higher infiltration of Tregs within their tumors often experienced longer periods of remission and improved overall survival. This anomaly stood in stark contrast to nearly every other solid tumor type, leaving researchers grappling for an explanation. The MSK team’s findings now offer that long-sought clarity, moving beyond a simple headcount of Treg cells to an intricate understanding of their functional diversity.
A Decades-Long Quest: Unraveling Immune Tolerance
This pivotal study is the culmination of more than two decades of pioneering research by Dr. Alexander Rudensky, widely recognized as one of the world’s foremost experts on regulatory T cells. His seminal work laid the foundation for our understanding of Treg cell biology, establishing their critical role in maintaining immune tolerance. Early in his career, Dr. Rudensky’s lab was instrumental in identifying the molecular mechanisms by which Treg cells are generated, how they exert their suppressive functions, and how their dysregulation can contribute to both autoimmune diseases and cancer progression. This extensive body of knowledge provided the essential context for his team to tackle the colorectal cancer paradox.
The current study was a collaborative effort, spearheaded by first authors Xiao Huang, PhD, a postdoctoral researcher in the Rudensky Lab; Dan Feng, MD, PhD, a former MSK Medical Oncology fellow now at the Icahn School of Medicine at Mount Sinai; and Sneha Mitra, PhD, a postdoctoral researcher in the lab of computational biologist Christina Leslie, PhD, the study’s other senior author. This interdisciplinary approach, combining deep immunological expertise with cutting-edge computational biology, was crucial in dissecting the complex cellular landscape of the tumor microenvironment.
Targeting the Most Prevalent Form of Colorectal Cancer
Colorectal cancer remains a formidable global health challenge, ranking as the second leading cause of cancer-related death when statistics for men and women are combined, according to the American Cancer Society. The MSK researchers strategically focused their investigation on the most common form of the disease: microsatellite stable (MSS) colorectal cancer with proficient mismatch repair (MMRp). This subtype accounts for a substantial 80% to 85% of all colorectal cancers.
Unfortunately, MSS-MMRp tumors are notoriously difficult to treat with current checkpoint inhibitor immunotherapies. These therapies, which work by disinhibiting the immune system’s T cells, have revolutionized cancer treatment for many other malignancies. However, their efficacy in MSS-MMRp CRC has been limited, largely due to the "cold" immune microenvironment typically found in these tumors—meaning they have fewer immune cells ready to attack the cancer. This contrasts sharply with microsatellite unstable (MSI-H) and mismatch repair deficient (MMRd) colorectal cancers, which represent a smaller subset but are often highly responsive to immunotherapy, sometimes allowing patients to avoid aggressive surgery, chemotherapy, and radiation. The lack of effective immunotherapy options for the majority of CRC patients underscores the urgent need for novel approaches, which this study now provides.
The Bifurcation: Two Faces of Regulatory T Cells
To systematically unravel the unique immune landscape of common colorectal cancers, the research team employed a sophisticated mouse model. This model, meticulously developed at MSK, faithfully recapitulates the genetic alterations, behavioral characteristics, and intricate immune environment observed in human colorectal tumors, providing a robust platform for mechanistic studies.
Their key discovery was the identification of two distinct populations of tumor-associated Treg cells. The first group, termed "IL-10-positive Treg cells," is characterized by its production of interleukin-10 (IL-10), a potent signaling molecule or cytokine known for its anti-inflammatory properties. The second group, "IL-10-negative Treg cells," notably lacks this IL-10 production.
Through a series of meticulously designed experiments involving the selective removal of each Treg subtype, the researchers meticulously charted their divergent impacts on tumor growth.
-
The Beneficial Subtype: IL-10-positive Treg cells: These cells were found to actively slow down tumor progression. Their mechanism of action involves reducing the activity of Th17 cells, another type of immune cell that produces interleukin 17 (IL-17). IL-17, unlike IL-10, acts as a growth signal, actively fueling tumor expansion. By dampening Th17 activity and IL-17 production, IL-10-positive Treg cells effectively deprive the tumor of a critical growth factor. Intriguingly, these protective Treg cells were observed to be more prevalent in the healthy tissue immediately adjacent to the tumor, suggesting a role in maintaining local immune balance. When the scientists selectively eliminated these IL-10-positive Treg cells, tumors in the mouse models exhibited accelerated growth, underscoring their crucial protective function.
-
The Harmful Subtype: IL-10-negative Treg cells: In stark contrast, the IL-10-negative Treg cells exerted a detrimental effect on immune control. These cells were found to potently suppress powerful immune defenders, most notably cytotoxic CD8+ T cells, which are renowned for their direct cancer-fighting capabilities. By stifling the activity of these "killer" T cells, the IL-10-negative Tregs effectively create an immunosuppressive environment within the tumor, allowing cancer cells to evade destruction. This harmful subtype was predominantly located within the tumor itself, strategically positioned to neutralize anti-cancer immunity. When these IL-10-negative Treg cells were eliminated, a dramatic reduction in tumor size was observed, confirming their role as critical enablers of tumor growth.
Rigorous Validation: From Mouse Models to Human Patients
To ensure the clinical relevance of their findings, the MSK team meticulously validated their observations using human tumor samples derived from patients with colorectal cancer. Their analysis unequivocally confirmed the presence of these two distinct populations of IL-10-positive and IL-10-negative Treg cells within human CRC tissues, mirroring the cellular divisions identified in the mouse models.
Further bolstering their case, the researchers analyzed outcome data from over 100 colorectal cancer patients. This retrospective analysis provided compelling clinical evidence: patients whose tumors contained higher levels of the beneficial IL-10-positive Treg cells consistently exhibited longer overall survival. Conversely, patients whose tumors were enriched with the harmful IL-10-negative Treg cells experienced poorer outcomes. This direct correlation between Treg subtype prevalence and patient prognosis powerfully validates the functional distinctions observed in the experimental models.
"This research shows how important these positive cells are," Dr. Huang emphasizes. "And it highlights the need to develop therapies that can selectively eliminate the harmful Tregs while preserving the helpful ones." This sentiment encapsulates the essence of precision immunotherapy—a targeted approach that aims to fine-tune the immune response rather than broadly suppress or activate it.
A New Therapeutic Frontier: Selectively Targeting Harmful Tregs
The implications of these findings for future colorectal cancer treatment are profound, suggesting a promising new avenue for improving outcomes for the majority of patients, particularly those with MSS-MMRp tumors who currently lack effective immunotherapy options.
The researchers identified a crucial distinguishing marker: the IL-10-negative Treg cells, the harmful subtype that suppresses anti-cancer immunity and is primarily localized within tumors, express high levels of a protein called CCR8. This discovery is particularly exciting because it offers a tangible target for therapeutic intervention.
This insight builds upon earlier foundational work from Dr. Rudensky’s lab, led by breast cancer surgeon George Plitas, MD. Their previous research demonstrated that CCR8 is also highly expressed on tumor-infiltrating Treg cells in breast cancer and numerous other human malignancies. That pioneering work initially proposed that antibodies could be engineered to selectively deplete these harmful CCR8-expressing Treg cells. The premise is elegant: by specifically eliminating the detrimental Tregs, the immune system would be freed to mount a robust anti-tumor attack, while the beneficial Tregs—those not expressing CCR8 or expressing it at lower levels—would remain intact to maintain essential immune tolerance.
"This idea of using CCR8-depleting antibodies, which was pioneered at MSK, is the main target of global efforts to bring regulatory T cell-based immunotherapy to the clinic," Dr. Rudensky explains, highlighting the international scientific community’s recognition of this strategy’s potential. Indeed, multiple clinical trials are currently underway at MSK and other leading institutions worldwide, rigorously testing this approach. These trials are evaluating CCR8-targeting antibodies both as monotherapy and in combination with existing immunotherapies, aiming to amplify their anti-tumor effects. The new study on colorectal cancer significantly strengthens the rationale for deploying this precision strategy in CRC and expands its potential applicability to a broader spectrum of cancers.
Beyond Colorectal Cancer: Broadening the Horizon
The MSK team did not stop at colorectal cancer. Driven by curiosity about the broader implications of their findings, they extended their analysis to a comprehensive dataset of T cells from 16 different cancer types. Their investigation revealed that similar divisions between IL-10-positive and IL-10-negative Treg cells—and thus, potentially opposing functions—were discernible in several other cancers. These included malignancies affecting the skin and the lining of the mouth, throat, and stomach.
"What these tissues have in common is that immune cells play a critical role in constantly defending and repairing them as they’re exposed to microbes and environmental stresses," notes Dr. Mitra, who led the complex computational data analysis and is co-mentored by Dr. Leslie and Dr. Rudensky. This shared characteristic of "barrier tissues" suggests a conserved immune mechanism for maintaining homeostasis in environments under constant assault. Consequently, the researchers propose that therapeutic strategies designed to remove the harmful IL-10-negative Treg cells in colorectal cancer could very well prove effective against these other barrier tissue cancers, opening up exciting new avenues for treatment.
The Nuance of Metastasis: A Different Immune Landscape
While the study offers immense hope for primary colorectal tumors, the researchers also delved into the complexities of metastatic disease. When they examined colorectal cancer that had spread to the liver—a common site for CRC metastasis—they observed a distinctly different immune pattern.
In these metastatic liver tumors, the harmful IL-10-negative Treg cells were found to greatly outnumber their helpful IL-10-positive counterparts. This imbalance suggests a profound shift in the tumor microenvironment once the cancer has metastasized. Crucially, unlike in primary tumors where selective targeting is paramount, removing all Treg cells in this metastatic context resulted in the shrinkage of liver metastases. This outcome highlights that the immune landscape can vary significantly not only between different tumor types but also between primary and metastatic sites of the same cancer. This finding underscores the critical need for treatment strategies that are finely tailored, accounting for both the specific tissue involved and, critically, the stage of disease progression.
Expert Perspectives and the Road Ahead
The MSK study represents a monumental leap forward in understanding the intricate role of regulatory T cells in cancer immunology. By resolving the long-standing paradox of Tregs in colorectal cancer, it provides a clear roadmap for developing more effective and precise immunotherapies. The identification of CCR8 as a specific marker for harmful Tregs offers a direct therapeutic target, with ongoing clinical trials already exploring its potential.
The collaborative spirit that drove this research, involving immunologists, medical oncologists, and computational biologists, exemplifies the cutting-edge approach needed to tackle complex diseases like cancer. The potential extension of these findings to other barrier tissue cancers further amplifies the study’s impact, promising a broader revolution in cancer care.
"This research marks a turning point in our understanding of colorectal cancer immunity," Dr. Rudensky concludes. "It moves us closer to a future where we can selectively modulate the immune system to unleash its full power against cancer, while preserving the delicate balance necessary for health." The journey from laboratory discovery to clinical application is long and arduous, but this study provides a powerful new compass, guiding researchers toward more intelligent and effective ways to treat cancer.
Collaborative Excellence and Funding
Additional authors contributing to this impactful study include Emma Andretta, Nima Hooshdaran, Aazam Ghelani, Eric Wang, Joe Frost, Victoria Lawless, Aparna Vancheswaran, Qingwen Jiang, Cheryl Mai, and Karuna Ganesh. The Integrated Genomics Operation and the Single Cell Research Initiative at MSK were instrumental in providing key technological support for the research.
This groundbreaking work received generous financial support from several prestigious institutions, including the National Cancer Institute (P30 CA008748, U54 CA274492, T32 CA009512), the National Institute of Allergy and Infectious Diseases (AI034206), the Ludwig Center for Cancer Immunotherapy at MSK, the Howard Hughes Medical Institute, the Cancer Research Institute, and a Marie-José Kravis Fellowship in Quantitative Biology.
Disclosures
Dr. Rudensky serves on scientific advisory boards and holds equity in Sonoma Biotherapeutics, RAPT Therapeutics, Coherus Oncology, Santa Ana Bio, Odyssey Therapeutics, and Nilo Therapeutics. He is also a scientific advisory board member of Amgen, BioInvent, and Vedanta Biosciences, has consulted for AbbVie, and serves as an editor of the Journal of Experimental Medicine and an editorial advisor to Immunity.
Dr. Rudensky and Dr. Plitas are inventors on patents and patent applications held by MSK related to CCR8-based therapeutic depletion of tumoral Treg cells and novel antibodies against CCR8.
About the Author
